Medium materiality6/10
Truist Upgrades Edwards Lifesciences to Buy
Why it may matterVerify against the original reporting
Bullish on the explicit upgrade, with moderate indicated upside.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Truist upgraded EW to Buy and set a $113 target, about 19% above the posted price of $95.19. The upgrade is a clear positive rating change, though the target remains an analyst opinion.
- Upgrade to Buy; $113 target versus $95.19 posted price.
Key facts
- 01
Target: $113
- 02
Posted price: $95.19
- 03
Analyst firm: Truist Financial
- 04
Analyst: Richard Newitter
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.